Skip to main content

memo - Magazine of European Medical Oncology OnlineFirst articles

07.05.2021 | short review Open Access

Are there still indications for whole brain irradiation in 2021?

Brain metastases (BM) are the most frequent intracranial tumors in adults. About 10–20% of the patients with cancer will develop them. Historically, most of the patients with brain metastases were treated with whole brain radiotherapy (WBRT). The …

Karin Dieckmann, Harald Herrmann

04.05.2021 | case report

Unique gastrointestinal stromal tumor with PDGFRA D842Y mutation—evaluation of in vivo sensitivity to imatinib

Most gastrointestinal stromal tumors (GISTs) are associated with molecular changes in two genes, KIT and platelet-derived growth factor receptor‑α (PDGFRA). However, only 5–10% of GISTs harbor PDGFRA mutation. Most tumors carry substitution …

Olga Kuczkiewicz-Siemion, Agnieszka Dansonka-Mieszkowska, Piotr Rutkowski, Anna Klimczak, Andrzej Tysarowski, Monika Prochorec-Sobieszek, Anna Szumera-Ciećkiewicz

04.05.2021 | editorial

memo—publisher’s report 2020

Dr. Alois Sillaber

30.04.2021 | short review Open Access

ESMO 2020: highlights in breast cancer

Despite the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, results of several pertinent studies in the field of breast cancer (BC) were presented in a virtual format at the 2020 European Society of Medical Oncology …

Rupert Bartsch

15.04.2021 | case report

Sphenoidal mucormycosis associated with large B-cell lymphoma: case report and literature review

Mucormycosis is a rare but potentially life-threatening disease. Common risk factors include diabetic ketoacidosis, malignancies and bone marrow transplant. In patients with hematological malignancies mucormycosis often occurs in a context of …

MD Anis Chaari, Esraa Turak, Mark Nashaat, Islam Aboayana, Vipin Kauts

08.04.2021 | original report

Update ESMO: gastric and esophageal cancer

During this year’s virtual congress of the European Society of Oncology (ESMO) some practice-changing abstracts were presented. Especially immunotherapy (IO) has found its way into the treatment of esophageal (EC) and gastric cancer (GC) in both …

MD Ulrich Popper, MD Holger Rumpold

08.04.2021 | review Open Access

CAR T cell therapy in solid tumors: a short review

Chimeric antigen receptor (CAR) T cell therapy has been established in the treatment of hematological malignancies. However, in solid tumors its efficacy remains limited. The aim of this article is to give an overview of the field of cell therapy …

M.D. Öykü Umut, M.D. Adrian Gottschlich, M.D. Stefan Endres, M.D. Sebastian Kobold

01.04.2021 | short review Open Access

Clinically relevant infections in hematology and oncology: bacterial infections and the role of novel antibiotics in times of multidrug resistance

Multidrug resistance of bacterial pathogens is an increasing problem wordwide, especially treatment of multidrug resistant (MDR) gramnegative bacteria is challenging. In the recent past, several new antibiotics as well as new betalactamase …

PD Dr. Gernot Fritsche

01.04.2021 | short review Open Access

Malnutrition and cancer, diagnosis and treatment

Malnutrition means a significant loss of weight and body resources, which results in an impairment of quality of life and prognosis [ 1 ]. Worldwide studies show that the prevalence of malnutrition in cancer patients ranges from about 20% to more …

Bsc. Mag. Angelika Beirer

01.04.2021 | short review Open Access

ESMO 2020 update: Pancreatic cancer

At the ESMO (European Society for Medical Oncology) 2020 several interesting albeit not practice-changing studies in the field of pancreatic cancer were presented. The Canadian phase II randomized PA.7 trial investigated the additional benefit of …

MD, PhD Elisabeth Sophie Bergen

01.04.2021 | case report Open Access

Death of unknown cause? Post-mortem diagnosis of fulminant course of an EBV-associated secondary hemophagocytic lymphohistiocytosis

HLH is a life-threatening disease, which is characterized by a dysregulated immune response with uncontrolled T cell and macrophage activation. The often fulminant course of the disease needs a fast diagnostic work-up to initiate as soon as …

Josia Fauser, Stefan Köck, Eberhard Gunsilius, Andreas Chott, Andreas Peer, Adelheid Ditlbacher, Gernot Fritsche, Michael Joannidis, Dominik Wolf, M.D., Ph.D. Andreas Pircher

31.03.2021 | short review Open Access

Novel immune checkpoints beyond PD-1 in advanced melanoma

In malignant diseases, targeting of immune checkpoints successfully changed the therapeutic landscape and helped to unleash anti-tumor T cell responses, resulting in durable clinical outcomes, but only in up to 50% of patients. The success of …

Nina Zila, Christoph Hoeller, Verena Paulitschke

31.03.2021 | short review Open Access

ESMO virtual congress 2020—highlights NSCLC

This year’s virtual version of the European Society for Medical Oncology (ESMO) presidential sessions included three “late breaking” non-small cell lung cancer (NSCLC) abstracts, discussing strategies for adjuvant therapy of localized disease and …

Barbara Kiesewetter

31.03.2021 | short review Open Access

DNA methylation as predictive marker of response to immunotherapy?

Immunotherapy is one of the major breakthroughs in cancer treatment. However, many patients do not benefit from this type of therapy. Thus, there is an urgent need for a strategy to predict treatment efficacy before start of therapy. The role of …

PhD, MSc. Gerwin Heller

24.03.2021 | review Open Access

Importance of performance status and physical activity in cancer patients

Dr. David Kiesl

16.03.2021 | short review Open Access

Leptomeningeal metastases from solid tumours

Leptomeningeal metastases from solid tumours are increasingly being diagnosed and require a careful assessment by an interdisciplinary neuro-oncological tumour board for adequate diagnosis, therapy planning and optimal care of the affected …

Silvia Hofer, Emilie Le Rhun

05.03.2021 | review

Cognitive impairment in cancer patients and survivors—clinical presentation, pathophysiology, diagnosis and management

Cognitive impairment by neurotoxic substances, administered alone or in a multidrug regimen, affects a large number of patients treated for noncentral nervous system cancer during and after chemotherapy with variable onset, severity and duration …

MD Markus Hutterer, Stefan Oberndorfer

12.02.2021 | short review Open Access

WHO classification of tumors of the nervous system: preview of the upcoming 5th edition

Identification of the underlying genetic and epigenetic alterations in an increasing number of tumors of the nervous system is contributing to a more clinically relevant classification. In the following article, the 7 cIMPACT-NOW publications …

Elisabeth J. Rushing

23.12.2020 | original report

Effect of the ABO blood groups on the development, clinical features and survival of multiple myeloma

Multiple myeloma (MM) is a cytogenetically heterogeneous and incurable plasma cell disease characterized by clonal proliferation of malignant plasma cells [ 1 ]. It accounts for approximately 10% of all hematological malignancies [ 2 ]. MM is …

M.D Mesut Göçer, Erdal Kurtoğlu

13.10.2020 | original report

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by clonal expansion and accumulation of mature B‑lymphocytes in peripheral blood, bone marrow, and secondary lymphoid tissues [ 1 ]. CLL is highly heterogeneous where some …

Manal Atef, MD/PhD Layla M. Saleh, Noha Eisa, Sameh Shamaa